Please assess the completion status of the following clinical trial:

Trial Title: The Use of Oxytocin, Carbetocin and Buccal Misoprostol in Patients Undergoing Elective Cesarean Section (CS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years or more.~2. Gestational age of pregnancy of 37 completed weeks or more.~3. Written and signed informed consent by the patient to participate in the study.~Exclusion Criteria:~1. fetal or maternal distress where, due to time constraints, it will not possible and/or appropriate to recruit or randomize.~2. Women undergoing caesarean section with general anesthesia are also excluded, because carbetocin is licensed for use with regional anaesthesia only.~3. Women planned to have any other type of uterine incision other than transverse lower segment.~4. Women with HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count), eclampsia, and epilepsy .~5. Women with placental abruption are excluded because there is a higher risk of hemorrhage with this condition and it was therefore felt to be inappropriate to recruit these women.~6. Women with thrombocytopenia, known coagulopathies, or receiving anticoagulant therapy.~7. Women with history of significant heart disease, a history or evidence of liver, renal, vascular disease or endocrine disease (other than gestational diabetes).~8. Women with history of hypersensitivity to oxytocin or carbetocin.~9. Women with any severe allergic condition or severe asthma.~10. Women with any contraindication to receiving prostaglandins, including known hypersensitivity to misoprostol or other prostaglandins (PGs) or glaucoma.~11. Mental condition rendering the patients unable to understand the nature, scope and possible consequences of the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Syntocinon (Type: ACTIVE_COMPARATOR): Drug is given just after delivery of the neonate during cesarean section.
- Carbetocin (Type: ACTIVE_COMPARATOR): Drug is given just after delivery of the neonate during cesarean section.
- Misoprostol (Type: ACTIVE_COMPARATOR): Drug is given just after delivery of the neonate during cesarean section.

Based on this trial design, predict the completion outcome and termination type (if applicable).